Preexposure and Postexposure Prophylaxis of Rabies With Adeno-Associated Virus Expressing Virus-Neutralizing Antibody in Rodent Models
oleh: Fei Huang, Fei Huang, Meishen Ren, Meishen Ren, Jie Pei, Jie Pei, Hong Mei, Hong Mei, Baokun Sui, Baokun Sui, Qiong Wu, Qiong Wu, Benjie Chai, Benjie Chai, Ruicheng Yang, Ruicheng Yang, Ming Zhou, Ming Zhou, Zhen F. Fu, Zhen F. Fu, Huiping Zhou, Ling Zhao, Ling Zhao
| Format: | Article |
|---|---|
| Diterbitkan: | Frontiers Media S.A. 2021-08-01 |
Deskripsi
Rabies, a fatal disease in humans and other mammals, is caused by the rabies virus (RABV), and it poses a public health threat in many parts of the world. Once symptoms of rabies appear, the mortality is near 100%. There is currently no effective treatment for rabies. In our study, two human-derived RABV-neutralizing antibodies (RVNA), CR57 and CR4098, were cloned into adeno-associated virus (AAV) vectors, and recombinant AAVs expressing RVNA were evaluated for postexposure prophylaxis after intrathecal injection into RABV-infected rats. At 4days post-infection with a lethal dose of RABV, 60% of the rats that received an intrathecal injection of AAV-CR57 survived, while 100% of the rats inoculated with AAV-enhanced green fluorescent protein (EGFP) succumbed to rabies. Overall, these results demonstrate that AAV-encoding RVNA can be utilized as a potential human rabies postexposure prophylaxis.